You can be a part of the U.S. Food and Drug Administration (FDA)ís Patient-Focused Drug Development meeting on Parkinsonís disease on September 22, 2015 from 1:30 to 5 p.m. at its headquarters in Silver Spring, Maryland.
The FDAís Patient-Focused Drug Development initiative aims to more systematically gather patientsí perspectives on their† disease and its impact on daily life, the types of treatment benefit that matter most to patients, and adequacy of the available therapies. The FDA is holding at least 20 public meetings, each focused on a specific disease area, and will prepare reports to summarize patientsí input. This information may play a role in future FDA decisions on approval of new treatments.
Patients are invited to attend the meeting in person or watch on webcast but must register by September 14. You also can apply to be a panelist.
The FDA is also accepting patient comments in reply to various questions on impact of disease and treatment options. The deadline for submission is November 23, and comments may be shared online or through regular mail.
Learn more about how you can contribute to the FDA Patient-Focused Drug Development meeting on Parkinsonís disease.